Advertisement
Canada markets closed
  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     
  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     
  • DOW

    38,460.92
    -42.77 (-0.11%)
     
  • CAD/USD

    0.7297
    -0.0000 (-0.00%)
     
  • CRUDE OIL

    82.80
    -0.01 (-0.01%)
     
  • Bitcoin CAD

    87,879.38
    -3,125.01 (-3.43%)
     
  • CMC Crypto 200

    1,387.41
    -36.69 (-2.58%)
     
  • GOLD FUTURES

    2,327.90
    -10.50 (-0.45%)
     
  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     
  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     
  • NASDAQ futures

    17,471.25
    -193.25 (-1.09%)
     
  • VOLATILITY

    15.97
    +0.28 (+1.78%)
     
  • FTSE

    8,040.38
    -4.43 (-0.06%)
     
  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     
  • CAD/EUR

    0.6818
    -0.0001 (-0.01%)
     

FDA raises concerns over Valeant's eye drop

A sign for the headquarters of Valeant Pharmaceuticals International Inc is seen in Laval, Quebec June 14, 2016. REUTERS/Christinne Muschi (Reuters)

(Reuters) - Valeant Pharmaceuticals International said on Friday U.S. regulators have raised concerns over a new eye drop manufactured at a Bausch + Lomb facility in Florida. The U.S. Food and Drug Administration, in a complete response letter (CRL) regarding the eye drop for a type of glaucoma, raised concerns over Current Good Manufacturing Practice at the unit. The letter did not identify any efficacy or safety issues with the eye drop, a latanoprostene bunod ophthalmic solution. Valeant said it intends to meet the regulators and resolve these concerns, the company said in a statement. Eye care unit Bausch + Lomb is one of Valeant's core assets and a franchise to build on, billionaire investor and Valeant board member Bill Ackman said last week. (Reporting by Ismail Shakil in Bengaluru; Editing by Sunil Nair)